Figure 2.
Proposed neuropathy dose-adjustment algorithm for (A) paclitaxel, (B) nab-paclitaxel, and (C) ixabepilone. Dose reduction or discontinuation scenarios were chosen for the algorithm such that the predicted proportion of patients with a neuropathy score ≥8 on C7D1 is at least 30% fewer compared to no dose reduction. C, cycle; D, day.